SCYNEXIS, Inc.’s SEC filings document a biotechnology company with clinical-stage development programs in rare kidney disease and antifungal medicine. Its reports and current-event filings cover the acquired PXL-770, now SCY-770, AMPK activator assets for ADPKD; SCY-247 clinical and regulatory disclosures; and license arrangements involving ibrexafungerp and BREXAFEMME® with GSK.
SCYNEXIS filings also describe common-stock capitalization, material agreements, risk factors, operating and financial results, and Nasdaq-listed common stock. Proxy materials and Form 8-K reports cover shareholder voting matters, governance, board composition, executive compensation, auditor ratification, and proposed certificate-amendment matters affecting the company’s equity structure.
SCYNEXIS (Nasdaq: SCYX) disclosed receipt of a Nasdaq bid-price deficiency notice on 20 Jun 2025 after its shares closed below $1.00 for 30 straight sessions.
The company has 180 days (until 17 Dec 2025) to lift the bid to at least $1 for 10 consecutive trading days. If unsuccessful, it may transfer to the Nasdaq Capital Market for another 180-day cure or face delisting, subject to appeal.
- Current Nasdaq Global Market listing remains unaffected.
- Management can pursue a reverse stock split or other actions to regain compliance.
- The notice heightens liquidity and funding risk and could deter institutional holders.